Education
About Us
Working with TipRanks
Follow Us
scPharmaceuticals Inc (SCPH)
NASDAQ:SCPH
SCPH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.94 - $6.28
Previous CloseN/A
Volume61.66K
Average Volume (3M)346.98K
Market Cap
$263.83M
Enterprise Value$216.31M
Total Cash (Recent Filing)$40.81M
Total Debt (Recent Filing)$52.45M
Price to Earnings (P/E)―
Beta1.32
Next Earnings
Nov 05, 2025EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding53,298,298
10 Day Avg. Volume431,532
30 Day Avg. Volume346,984
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.82
Enterprise Value/Revenue4.33
Enterprise Value/Gross Profit6.32
Enterprise Value/Ebitda-2.62
Forecast
1Y Price Target
$13.75Price Target Upside198.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Financial PerformanceRevenue of $16.0M exceeded expectations, up 99.2% compared to the previous year.
Market AdoptionNephrologists prove to be fast adopters of Furoscix, contributing to increased sales and shipment volumes.
Product LaunchThe launch for Furoscix in Chronic Kidney Disease is progressing faster than the initial launch for heart failure.
Bears Say
CybersecurityThe launch, which was negatively impacted by the Change Healthcare cyberattack last year, has now hit its stride.
Operational ChallengesThe autoinjector program remains on track for sNDA submission, which will drive increased penetration with ~75% reduction in COGS and treatment time reduction.
scPharmaceuticals News
SCPH FAQ
What was scPharmaceuticals Inc’s price range in the past 12 months?
scPharmaceuticals Inc lowest stock price was $1.94 and its highest was $6.28 in the past 12 months.
What is scPharmaceuticals Inc’s market cap?
scPharmaceuticals Inc’s market cap is $263.83M.
When is scPharmaceuticals Inc’s upcoming earnings report date?
scPharmaceuticals Inc’s upcoming earnings report date is Nov 05, 2025 which is in 80 days.
How were scPharmaceuticals Inc’s earnings last quarter?
scPharmaceuticals Inc released its earnings results on Aug 07, 2025. The company reported -$0.34 earnings per share for the quarter, missing the consensus estimate of -$0.298 by -$0.042.
Is scPharmaceuticals Inc overvalued?
According to Wall Street analysts scPharmaceuticals Inc’s price is currently Undervalued.
Does scPharmaceuticals Inc pay dividends?
scPharmaceuticals Inc does not currently pay dividends.
What is scPharmaceuticals Inc’s EPS estimate?
scPharmaceuticals Inc’s EPS estimate is -0.24.
How many shares outstanding does scPharmaceuticals Inc have?
scPharmaceuticals Inc has 53,298,298 shares outstanding.
What happened to scPharmaceuticals Inc’s price movement after its last earnings report?
scPharmaceuticals Inc reported an EPS of -$0.34 in its last earnings report, missing expectations of -$0.298. Following the earnings report the stock price went down -7.585%.
Which hedge fund is a major shareholder of scPharmaceuticals Inc?
Currently, no hedge funds are holding shares in SCPH
scPharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.75 (198.91% Upside)
$13.75 (198.91% Upside)
Blogger Sentiment
Bullish
SCPH Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 1.4%
Last 30 Days ▼ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.09%
12-Months-Change
Fundamentals
Return on Equity
-934.02%
Trailing 12-Months
Asset Growth
22.61%
Trailing 12-Months
Company Description
scPharmaceuticals Inc
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
SCPH Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant revenue growth and successful launches in nephrology and IDN segments, contributing to a positive outlook. However, challenges such as increased gross to net discounts and declining cash reserves were noted. Despite these challenges, the positive achievements and strategic advancements suggest a generally positive sentiment.View all SCPH earnings summariesSCPH Stock 12 Month Forecast
Average Price Target
$13.75
▲(198.91% Upside)
Technical Analysis
Ownership Overview
18.21% Insiders
7.04% Mutual Funds
0.09% Other Institutional Investors
68.56% Public Companies and Individual Investors